Zynex, Inc. (NASDAQ:ZYXI) CEO Sells $18,180.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.09, for a total value of $18,180.00. Following the completion of the transaction, the chief executive officer now directly owns 14,609,662 shares in the company, valued at $132,801,827.58. The trade was a 0.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 13th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.37, for a total value of $16,740.00.
• On Friday, November 8th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.77, for a total transaction of $17,540.00.
• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Monday, November 4th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.67, for a total transaction of $17,340.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.63, for a total value of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total value of $17,840.00.

Zynex Trading Down 0.5 %

Shares of ZYXI opened at $8.09 on Friday. The stock has a market cap of $257.67 million, a PE ratio of 53.93 and a beta of 0.53. The stock has a 50 day simple moving average of $8.23 and a 200-day simple moving average of $8.92. Zynex, Inc. has a 1 year low of $7.15 and a 1 year high of $13.77. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last announced its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. On average, sell-side analysts predict that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Zynex

Several institutional investors and hedge funds have recently made changes to their positions in ZYXI. Millennium Management LLC increased its holdings in shares of Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after acquiring an additional 118,615 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Zynex by 68.7% in the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the period. GSA Capital Partners LLP raised its holdings in Zynex by 72.7% during the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock worth $652,000 after buying an additional 33,649 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Zynex by 22.3% in the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after buying an additional 26,368 shares during the period. Finally, WINTON GROUP Ltd boosted its holdings in shares of Zynex by 147.6% in the second quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after buying an additional 21,960 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

Analyst Upgrades and Downgrades

ZYXI has been the subject of a number of research analyst reports. HC Wainwright upped their price target on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.